» Articles » PMID: 20558502

Meta-analysis of the Efficacy and Safety of Sativex (nabiximols), on Spasticity in People with Multiple Sclerosis

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2010 Jun 19
PMID 20558502
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the efficacy of Sativex (USAN: nabiximols) in the alleviation of spasticity in people with multiple sclerosis.

Methods: The results from three randomized, placebo-controlled, double-blind parallel group studies were combined for analysis.

Patients: 666 patients with multiple sclerosis and spasticity.

Measures: A 0-100 mm Visual Analogue Scale (VAS, transformed to a 0-10 scale) or a 0-10 Numerical Rating Scale (0-10 NRS) was used to measure spasticity. Patients achieving a > or =30% improvement from baseline in their spasticity score were defined as 'responders'. Global impression of change (GIC) at the end of treatment was also recorded.

Results: The patient populations were similar. The adjusted mean change of the numerical rating scale from baseline in the treated group was -1.30 compared with -0.97 for placebo. Using a linear model, the treatment difference was -0.32 (95% CI -0.61, -0.04, p = 0.026). A statistically significant greater proportion of treated patients were responders (odds ratio (OR) = 1.62, 95% CI 1.15, 2.28; p = 0.0073) and treated patients also reported greater improvement: odds ratio 1.67 (95% CI 1.05, 2.65; p = 0.030). High numbers of subjects experienced at least one adverse event, but most were mild to moderate in severity and all drug-related serious adverse events resolved.

Conclusion: The meta-analysis demonstrates that nabiximols is well tolerated and reduces spasticity.

Citing Articles

Therapeutic use of medical Cannabis in neurological diseases: a clinical update.

Hidding U, Mainka T, Buhmann C J Neural Transm (Vienna). 2023; 131(2):117-126.

PMID: 38015317 PMC: 10791790. DOI: 10.1007/s00702-023-02719-1.


Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy.

Voicu V, Brehar F, Toader C, Covache-Busuioc R, Corlatescu A, Bordeianu A Biomolecules. 2023; 13(9).

PMID: 37759788 PMC: 10526757. DOI: 10.3390/biom13091388.


Molecular and Cellular Mechanisms of Action of Cannabidiol.

Martinez Naya N, Kelly J, Corna G, Golino M, Abbate A, Toldo S Molecules. 2023; 28(16).

PMID: 37630232 PMC: 10458707. DOI: 10.3390/molecules28165980.


Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.

Kleiner D, Horvath I, Bunduc S, Gergo D, Lugosi K, Fehervari P Curr Neuropharmacol. 2023; 21(12):2505-2515.

PMID: 37519000 PMC: 10616923. DOI: 10.2174/1570159X21666230727094431.


Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population.

Rainka M, Aladeen T, Mattle A, Lewandowski E, Vanini D, McCormack K Int J MS Care. 2023; 25(3):111-117.

PMID: 37250194 PMC: 10211357. DOI: 10.7224/1537-2073.2022-006.